[68Ga]Ga-PSMA-11 is the first radiopharmaceutical approved by the FDA for PET imaging of PSMA-positive prostate cancer, and [177Lu]Lu-PSMA-617 has also been used for PSMA-targeted therapy [74,75,76,77]. This evidence concerns the gene FOLH1 and prostate carcinoma.